Andy Scharenberg

Andy Scharenberg

Co-founder & Chief Executive Officer at Umoja Biopharma
Seattle, Washington, United States

Andy Scharenberg is Chief Executive Officer at Umoja Biopharma and Executive Partner at MPM BioImpact. He co-founded Generation Bio and Pregenen, and has served as Chief Scientific Officer at Casebia Therapeutics and Cellectis therapeutics. He has chaired scientific advisory boards at Alpine Immune Sciences and Generation Bio, and was a professor at the University of Washington and principal investigator at Seattle Children's Hospital and Research Institute.

Recent coverage

Front-page news, podcasts and videos about Andy

See all 6

Organizations

See all 10
  • Umoja Biopharma logo
    Umoja Biopharma Executive Officer, Director 2021–present, Co-founder & Chief Executive Officer 2019–present · current
  • MPM BioImpact Executive Partner 2019–present · current
  • Casebia Therapeutics Chief Scientific Officer 2017–2019 · past

Education

  • University of North Carolina School of Medicine MD, Medicine · 1991–1993

Online

Questions about Andy Scharenberg

Who is Andy Scharenberg?

Andy Scharenberg is co-founder and chief executive officer at Umoja Biopharma and an executive partner at MPM BioImpact, both since 2019. Andy previously served as chief scientific officer at Casebia Therapeutics from 2017 to 2019 and Cellectis therapeutics from 2011 to 2014.

What is Andy Scharenberg known for?

Andy Scharenberg is known for co-founding Generation Bio and Pregenen and for work in pediatrics and immunology. Andy was a professor of pediatrics and immunology at University of Washington and a principal investigator at Seattle Children's Hospital and Research Institute from 2000 to 2020.

What has Andy Scharenberg been in the news for?

Umoja Biopharma reported in April 2026 that it would unveil UB-VV500, an in vivo BCMA × GPRC5D CAR T therapy for multiple myeloma, at ASGCT.

Which organizations is Andy Scharenberg associated with?

Andy Scharenberg is associated with 10 organizations, including Umoja Biopharma as co-founder and chief executive officer since 2019 and MPM BioImpact as executive partner since 2019. Andy was chief scientific officer at Casebia Therapeutics from 2017 to 2019 and Cellectis therapeutics from 2011 to 2014, and co-founded Generation Bio in 2017 and Pregenen in 2009.

Where did Andy Scharenberg study?

Andy Scharenberg studied medicine at University of North Carolina School of Medicine from 1991 to 1993, earning an MD.

Where is Andy Scharenberg based?

Andy Scharenberg is based in Seattle, Washington, United States.